Shada Khalid Alanazi

Shada Khalid Alanazi

Auto-generated profile, based on publicly available information

Shada Khalid Alanazi

King Faisal University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in JMIR Preprints
Verified
Preprint
Open access
SAShada Khalid Alanazi
Shada Khalid Alanazi
LALama Alanazi
Lama Alanazi
ZAZahra Saleh Alsindi
Zahra Saleh Alsindi
SASarah Anwar Almulla
Sarah Anwar Almulla
NANasser A Almulhim
Nasser A Almulhim
HAheba alojail
heba alojail
BACKGROUND Artificial intelligence (AI) applications in dermatology show promising potential for diagnostic support and healthcare accessibility, yet successful implementation requires understanding public acceptance patterns. Limited research has examined attitudes toward AI specifically in dermatology within culturally diverse populations. This study assessed Saudi public attitudes toward AI in dermatology to inform implementation strategies for similar healthcare contexts. OBJECTIVE To evaluate knowledge, attitudes, and acceptance factors regarding AI applications in dermatology among Saudi adults and identify demographic and experiential predictors of AI adoption intentions. METHODS We conducted a cross-sectional online survey among Saudi adults aged 18 years and older from May 21 to June 5, 2025. The survey included 30 items divided into three sections: demographics (10 items), attitudes toward AI in dermatology (20 items on a 5-point Likert scale), and system priority ratings (6 items on a 5-point importance scale). We employed convenience and snowball sampling through social media platforms. For data analysis, we used descriptive statistics, one-way ANOVA for group comparisons, and binary logistic regression to identify predictors of high behavioral intention. We set the statistical significance at P < .05. RESULTS The study included 668 participants (61.1% female, 45.4% aged 18-24 years). Participants demonstrated high overall acceptance of AI in dermatology (mean score: 74.48 ± 10.20, Cronbach's α = 0.868). Strong preferences emerged for physician-supervised AI systems rather than autonomous implementations, with medical supervision receiving the highest endorsement (4.27 ± 0.87), followed by explainable AI decisions (4.12 ± 0.82) and physician authority during diagnostic disagreements (4.11 ± 0.86). While recognizing AI's potential benefits for healthcare access in remote areas (3.92 ± 0.94) and cost reduction (3.81 ± 0.86), participants expressed moderate enthusiasm for personal use (3.60 ± 0.97) and reservations about independent AI diagnosis (3.26 ± 0.97). System priorities emphasized privacy protection (56.4% rated as very important) and diagnostic accuracy (55.8%), followed by cultural compatibility (49.3%) and decision transparency (47.2%). Age significantly influenced acceptance (P = .009), with younger adults (18-24 years) showing the highest acceptance (75.96 ± 9.38). Technology interest demonstrated the strongest associations with both acceptance and perceived importance (P < .001). Healthcare professionals valued AI's importance more than general participants (P = .004) while maintaining similar acceptance levels. Gender, geographic region, education level, and dermatological experience showed no significant associations with acceptance patterns. CONCLUSIONS Saudi adults demonstrate predominantly positive yet nuanced attitudes toward dermatological AI, with strong preferences for collaborative physician-AI models over autonomous systems. Successful implementation requires prioritizing transparent, secure AI architectures with physician oversight, developing targeted educational initiatives across demographic groups, and ensuring cultural responsiveness in AI system design. These findings provide crucial baseline data for AI integration within Saudi Arabia's Vision 2030 healthcare objectives and offer insights relevant for culturally diverse healthcare contexts globally.

20 July 2026 in Archives of Dermatological Research
Verified
Journal Article
Closed access
AAAbdullah Mohammed Almeziny
Abdullah Mohammed Almeziny
MAMaha Alkharisi
Maha Alkharisi
SAShada Khalid Alanazi
Shada Khalid Alanazi
SASara Mahfoud Alghamdi
Sara Mahfoud Alghamdi
MAMohammed A. Alahmadi
Mohammed A. Alahmadi
FAFares Abdulmajed Alkhayal
Fares Abdulmajed Alkhayal

1 July 2025 in Electronic Journal of General Medicine
Verified
Journal Article
Open access
PDF file
AMAbdullah Moktar
Abdullah Moktar
SAShada Alanazi
Shada Alanazi
Sarah Anwar AlmullaSarah Anwar Almulla
Sarah Anwar Almulla
MAMai Saadoon Alsaadoon
Mai Saadoon Alsaadoon
Pemphigus vegetans (PVeg), which affects < 2% of pemphigus cases, presents a therapeutic challenge when refractory to conventional treatments. Herein, we describe the case of a 58-year-old woman diagnosed with Hallopeau-type PVeg who demonstrated a complete response to intravenous immunoglobulin (IVIG) after failing multiple conventional therapies. The patient exhibited vegetative plaques at multiple sites, with notable nail involvement. Her disease remained poorly controlled despite a 7-year course of systemic corticosteroids, immunosuppressants, and rituximab. Two courses of IVIG (5% concentration, 2 g/kg) resulted in the complete resolution of the disease. This case highlights IVIG’s therapeutic potential in refractory PVeg and emphasizes the importance of recognizing atypical manifestations, including nail involvement. While this single case yielded promising results, future studies must validate the role of IVIG in the management of treatment-resistant PVeg.

1 February 2026 in Digital Health
Verified
Journal Article
Open access
SAShada Khalid Alanazi
Shada Khalid Alanazi
MAMaha Mohammed Alkharisi
Maha Mohammed Alkharisi
HAHind Bader Alshalhoob
Hind Bader Alshalhoob
WAWaad Abdulelah Alduraywish
Waad Abdulelah Alduraywish
Sarah Anwar AlmullaSarah Anwar Almulla
Sarah Anwar Almulla
IAIbrahim Alfuraih
Ibrahim Alfuraih
Background: Artificial intelligence (AI) methods are increasingly used to assess hair and scalp disorders. However, the range of clinical tasks addressed, model performance, and methodological robustness across indications remains unclear. Methods: We conducted a systematic review following PRISMA guidance. PubMed/MEDLINE, Web of Science, Scopus, and Cochrane CENTRAL were searched from inception to December 2025, with additional reference screening. We included interventional or observational studies that developed, validated, or clinically evaluated AI and machine learning (ML) models using scalp photography, dermoscopy/trichoscopy, or related imaging modalities and reported extractable performance or agreement outcomes. Risk of bias was assessed using QUADAS-2 for diagnostic studies, PROBAST+AI for prediction models, and the NIH/NHLBI tool for the single before–after trial. Due to methodological heterogeneity, findings were synthesized narratively. Results: From 2,256 records, 15 studies published between 2020 and 2026 met the inclusion criteria, with seven published in 2025 or 2026. Thirteen were retrospective image analysis or model development studies, and two were prospective investigations. Seven studies addressed diagnostic classification, and six focused on severity scoring or quantitative assessment; prognosis and treatment response were each evaluated in one study. Deep learning approaches, predominantly transfer-learned convolutional neural networks, were most common, alongside segmentation frameworks and occasional traditional ML algorithms. Reported performance was generally high in controlled datasets and structured tasks, including strong agreement for automated Severity of Alopecia Tool (SALT) estimation and robust discrimination between psoriasis and seborrheic dermatitis. Conclusions: AI demonstrates promising potential for scalp disease diagnosis and objective severity quantification, particularly for automated SALT estimation and patterned hair-loss assessment. However, the current evidence base is dominated by retrospective single-source datasets with limited external validation, restricting confidence in generalizability and clinical implementation.